STEP 01
WHAT WE STANDARDIZE
Bring in the work
Run asset scouting, scientific diligence, clinical strategy, and decision packets on one evidence record.
→APP DATA OS · DRUG DEVELOPMENT OS · DRUG DEVELOPMENT OS UNIFIES ASSET SCOUTING, SCIENTIFIC DILIGENCE, CLINICAL STRATEGY, EVIDENCE REVIEW, AND DECISION GOVERNANCE IN ONE AUDITABLE WORKFLOW.
Every asset. Every claim. Every source.
Bring targets, assets, trials, publications, regulatory records, patents, company signals, data-room records, and reviewer judgment into one evidence fabric. Teams review the evidence, run diligence workers, and export decision packets with citations, hashes, provider modes, and audit manifests attached.
ACCEPTED FORMATS
assets / trials / papers / patents / decks
Start with the files and records the team already uses.
DECISION OWNER
Scientific reviewer
Keep the right specialist or approver on the work that needs judgment.
OUTCOME
Decision packet
Hand off one reviewed record instead of scattered notes.
HOW IT WORKS
Three steps. Asset or target in. Evidence review and diligence workers in the loop. Decision packet out.
Bring in the work. Standardize the step. Hand off a clean result.
STEP 02
WHAT WE REVIEW
Evidence behind each asset, trial, company, patent, clinical precedent, and portfolio decision is scattered across public sources, data rooms, decks, and reviewer notes.
Search live public biomedical providers, attach reviewed evidence, run diligence workers, and export a packet with citations, hashes, provider modes, and review state preserved.
→STEP 03
WHAT WE SIGN
Leave with a clean result
Get one drug-development decision packet with accepted evidence, reviewer gates, risks, gaps, clinical context, and source provenance attached.
WHY IT EXISTS
The reason a drug development os team buys the app.
Use this when asset scouting, diligence, clinical strategy, or portfolio decisions slow down because the evidence behind each call is scattered across public sources, internal records, decks, trial registries, patents, and reviewer notes.
THE PROBLEM
Use this when asset scouting, diligence, clinical strategy, or portfolio decisions slow down because the evidence behind each call is scattered across public sources, internal records, decks, trial registries, patents, and reviewer notes.
THE REVIEW MOTION
Asset or target in. Evidence review and diligence workers in the loop. Decision packet out.
THE OUTCOME
Provider record IDs, source URLs, content hashes, reviewer state, claims, risks, gaps, clinical facts, and packet manifests stay tied to the asset decision.
WHY TEAMS BUY IT
Bring targets, assets, trials, publications, regulatory records, patents, company signals, data-room records, and reviewer judgment into one evidence fabric. Teams review the evidence, run diligence workers, and export decision packets with citations, hashes, provider modes, and audit manifests attached.
FOCUS AREAS · THREE WINDOWS
The three places this app does the work.
Asset or target in. Evidence review and diligence workers in the loop. Decision packet out.
AREA · 01
Asset scouting
Start with the real asset or evidence set and the rules that matter.
- ↳Bring in assets / trials / papers / patents / decks without stripping away context.
- ↳Keep project constraints visible from the first step.
- ↳Give the team one clear place to start the review.
AREA · 02
Scientific diligence
Send the hard calls to the scientific, clinical, or portfolio reviewer.
- ↳Surface the cases that need human judgment.
- ↳Keep reviewer notes attached to the decision.
- ↳Make approvals, overrides, and escalations easy to explain later.
AREA · 03
Decision packet
Hand off a decision packet the next team can trust.
- ↳Export lineage, notes, and approval status together.
- ↳Save repeat failures as checks for the next run.
- ↳Deliver one clean packet for the next team or gate.
WORKFLOW · THREE STAGES
The walkthrough your team runs.
Provider record IDs, source URLs, content hashes, reviewer state, claims, risks, gaps, clinical facts, and packet manifests stay tied to the asset decision.
STAGE · 01
01
Bring in the asset or evidence set
Load the work, context, and rules into one record.
- ·Use assets / trials / papers / patents / decks.
- ·Capture the project rules before review starts.
- ·Keep the original context attached.
STAGE · 02
02
Review what needs judgment
Score the work and send the decisions that need judgment to the scientific, clinical, or portfolio reviewer.
- ·Highlight what can move fast and what cannot.
- ·Record reviewer notes and final calls.
- ·Keep the audit trail readable.
STAGE · 03
03
Export the decision packet
Package the approved result for the next team, approval gate, or audit request.
- ·Bundle the evidence with the decision.
- ·Save the same mistake as a future check.
- ·Hand off a packet someone else can inspect.
STARTS FROM
A model already suited to the workflow.
STARTER MODEL
Drug Development OS
Starts with live public adapters for clinical trials, literature, regulatory records, patents, chemistry, target validation, and public company intelligence, plus assisted web research and enterprise connector abstractions.
Reviewed asset decisions, diligence notes, clinical precedents, accepted evidence, rejected hypotheses, and packet outcomes become reusable decision memory for your own portfolio.
AuraOne helps map the first asset-to-packet loop. Your scientists, clinicians, portfolio leads, and reviewers still decide what advances.
READING · DRUG DEVELOPMENT OS · LIVE
00·00 INTAKEUSE THIS WHEN ASSET SCOUTING, DILIGESIGN 04·18
REVIEWER · EVIDENCE · OUTPUT
The work and the people who sign for it.
Specialist reviewers, the evidence they keep, and the result the next team consumes.
REVIEWER TYPE
scientific, clinical, or portfolio reviewer
ENTRY MOTION
Asset or target in. Evidence review and diligence workers in the loop. Decision packet out.
EVIDENCE PATTERN
Provider record IDs, source URLs, content hashes, reviewer state, claims, risks, gaps, clinical facts, and packet manifests stay tied to the asset decision.
OUTPUT SUMMARY
Get one drug-development decision packet with accepted evidence, reviewer gates, risks, gaps, clinical context, and source provenance attached.
PAINFUL STEP
Evidence behind each asset, trial, company, patent, clinical precedent, and portfolio decision is scattered across public sources, data rooms, decks, and reviewer notes.
WHAT YOU KEEP
Reviewed asset evidence, claims, risks, gaps, decision packets, provider provenance, and strategy memory your drug-development team can keep.
↳ WORKFLOW ARCHETYPES
asset scoutingscientific diligencedecision packetCONNECTED MODULES · INSIDE THE OS
What this app plugs into.
The drug development os app does not run alone. Each captured decision feeds into the AuraOne modules that govern release, memory, and review — one record, one standard, one packet.
№ 01 · MODULE
Models
№ 02 · MODULE
Workforce
№ 03 · MODULE
Regression Bank
№ 04 · MODULE
Control Center
ON THE RECORD · A DRUG DEVELOPMENT OS PROGRAM
“The review used to be the bottleneck. Now it’s the part of the workflow that moves the fastest. The record travels with the work.”
WHAT YOU KEEP
Your work. Your data. Your AI.
WORKFLOW
Real cases
Files, batches, and cases your team already runs. Not a demo.
DATA
Your tenant
In your VPC. Your keys. Your retention policy.
WEIGHTS
Yours to keep
Reviewed asset evidence, claims, risks, gaps, decision packets, provider provenance, and strategy memory your drug-development team can keep.
RELATED APPS
Same loop. Different wavelength.
DRUG DEVELOPMENT OS
Bring the workflow you want to own.
We'll map the workflow. Pick the starting model. Standardize the step. Hand you the result.
↳ STARTS FROM
Drug Development OS
↳ LEAVES WITH
Reviewed asset evidence, claims, risks, gaps, decision packets, provider provenance, and strategy memory your drug-development team can keep.